CN107787364A - 用于治疗癌症的治疗组合物及使用方法 - Google Patents

用于治疗癌症的治疗组合物及使用方法 Download PDF

Info

Publication number
CN107787364A
CN107787364A CN201680020049.0A CN201680020049A CN107787364A CN 107787364 A CN107787364 A CN 107787364A CN 201680020049 A CN201680020049 A CN 201680020049A CN 107787364 A CN107787364 A CN 107787364A
Authority
CN
China
Prior art keywords
cells
cancer
tumor
virus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680020049.0A
Other languages
English (en)
Chinese (zh)
Inventor
U.加利利
M.韦斯特比
S.肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai Jia Seoul Immune Co Ltd
Original Assignee
Ai Jia Seoul Immune Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Jia Seoul Immune Co Ltd filed Critical Ai Jia Seoul Immune Co Ltd
Publication of CN107787364A publication Critical patent/CN107787364A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01087—N-Acetyllactosaminide 3-alpha-galactosyltransferase (2.4.1.87), i.e. alpha-1,3-galactosyltransferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01057—Phosphatidylinositol alpha-mannosyltransferase (2.4.1.57)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680020049.0A 2015-04-07 2016-04-07 用于治疗癌症的治疗组合物及使用方法 Pending CN107787364A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1505860.5A GB201505860D0 (en) 2015-04-07 2015-04-07 Therapeutic compositions and methods of use for treating cancer
GB1505860.5 2015-04-07
PCT/GB2016/050973 WO2016162675A1 (en) 2015-04-07 2016-04-07 Therapeutic compositions and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
CN107787364A true CN107787364A (zh) 2018-03-09

Family

ID=53190234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680020049.0A Pending CN107787364A (zh) 2015-04-07 2016-04-07 用于治疗癌症的治疗组合物及使用方法

Country Status (14)

Country Link
US (2) US20180104288A1 (https=)
EP (1) EP3280798B1 (https=)
JP (2) JP2018512150A (https=)
KR (1) KR102544032B1 (https=)
CN (1) CN107787364A (https=)
BR (1) BR112017021700A2 (https=)
CA (1) CA2981925C (https=)
ES (1) ES2743952T3 (https=)
GB (1) GB201505860D0 (https=)
HK (1) HK1251009B (https=)
IL (1) IL254842B (https=)
MX (1) MX377211B (https=)
RU (1) RU2720984C2 (https=)
WO (1) WO2016162675A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112584849A (zh) * 2018-08-24 2021-03-30 杭州优善生物科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
WO2021139810A1 (en) * 2020-01-10 2021-07-15 The University Of Hong Kong Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof
CN113993531A (zh) * 2019-05-14 2022-01-28 癌康理生物制药株式会社 向肿瘤组织施加溶瘤病毒的方法以及施加用装置

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
CA3199581A1 (en) * 2020-11-30 2022-06-02 Neil H. Bander Cancer immunotherapies to promote hyperacute rejection
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
WO2026068773A1 (en) * 2024-09-27 2026-04-02 Repudio Ab Immunotherapy using ggta and nap

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
CN1756568A (zh) * 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
CN101056646A (zh) * 2004-11-12 2007-10-17 拜耳先灵医药股份有限公司 重组新城疫病毒
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
CN102548584A (zh) * 2009-05-06 2012-07-04 贝尔韦什生物医学研究学会 用于治疗癌症的溶瘤腺病毒
CN104093830A (zh) * 2011-04-15 2014-10-08 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
CN105779397A (zh) * 2014-12-22 2016-07-20 彭霞 溶瘤异源重组新城疫病毒及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9810904D0 (en) 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7338932B2 (en) * 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
US7820628B2 (en) 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
KR20150093775A (ko) * 2012-12-07 2015-08-18 노쓰 캐롤라이나 스테이트 유니버시티 베타 헥소실-전이효소 및 이의 이용

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
CN1756568A (zh) * 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
CN101056646A (zh) * 2004-11-12 2007-10-17 拜耳先灵医药股份有限公司 重组新城疫病毒
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
CN102548584A (zh) * 2009-05-06 2012-07-04 贝尔韦什生物医学研究学会 用于治疗癌症的溶瘤腺病毒
CN104093830A (zh) * 2011-04-15 2014-10-08 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
CN105779397A (zh) * 2014-12-22 2016-07-20 彭霞 溶瘤异源重组新城疫病毒及其制备方法与应用

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANNIINA KOSKI等: "Treatment of cancer patients with serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF", 《MOLECULAR THERAPY》 *
FUEYO J等: "A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo", 《ONCOGENE》 *
LUCY DERIY等: "In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the [alpha]1,3galactosyltransferase gene", 《CANCER GENE THERAPY》 *
MAXINE BAUZON等: "Armed therapeutic viruses- a disruptive therapy on the horizon of cancer immunotherapy", 《FRONT IMMUNOL》 *
SEBASTIAN TUVE等: "A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells", 《JOURNAL OF VIROLOGY》 *
SIMONA BRAMANTE等: "Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans", 《INTERNATIONAL JOURNAL OF CANCER》 *
URI GALILI等: "Anti-gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits", 《IMMUNOLOGY》 *
张唯等: "双靶向溶瘤腺病毒对肿瘤细胞及正常细胞的杀伤差异性研究", 《华东师范大学学报（自然科学版）》 *
王宏芳等: "双重靶向条件复制型腺病毒的包装及抗肿瘤作用 ", 《西安交通大学学报(医学版)》 *
韩明勇等主编: "《肿瘤分子靶向治疗学》", 31 August 2008, 济南出版社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112584849A (zh) * 2018-08-24 2021-03-30 杭州优善生物科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
CN113993531A (zh) * 2019-05-14 2022-01-28 癌康理生物制药株式会社 向肿瘤组织施加溶瘤病毒的方法以及施加用装置
WO2021139810A1 (en) * 2020-01-10 2021-07-15 The University Of Hong Kong Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof
CN115103905A (zh) * 2020-01-10 2022-09-23 香港大学 表达α-1,3-半乳糖基转移酶的重组病毒及其用途
CN115103905B (zh) * 2020-01-10 2025-02-21 香港大学 表达α-1,3-半乳糖基转移酶的重组病毒及其用途

Also Published As

Publication number Publication date
IL254842B (en) 2022-01-01
BR112017021700A2 (pt) 2018-07-24
EP3280798B1 (en) 2019-06-19
CA2981925A1 (en) 2016-10-13
RU2720984C2 (ru) 2020-05-15
KR20180015113A (ko) 2018-02-12
RU2017134519A (ru) 2019-04-04
WO2016162675A1 (en) 2016-10-13
JP2021045152A (ja) 2021-03-25
US12023362B2 (en) 2024-07-02
US20180104288A1 (en) 2018-04-19
MX377211B (es) 2025-03-07
JP7066812B2 (ja) 2022-05-13
ES2743952T3 (es) 2020-02-21
IL254842A0 (en) 2017-12-31
GB201505860D0 (en) 2015-05-20
US20200155626A1 (en) 2020-05-21
MX2017012867A (es) 2018-05-11
RU2017134519A3 (https=) 2019-10-10
EP3280798A1 (en) 2018-02-14
HK1251009B (en) 2020-06-26
JP2018512150A (ja) 2018-05-17
KR102544032B1 (ko) 2023-06-14
CA2981925C (en) 2025-03-11

Similar Documents

Publication Publication Date Title
JP7066812B2 (ja) 癌を治療するための治療用組成物及び使用方法
HK1251009A1 (en) Therapeutic compositions of use for treating cancer
US12318418B2 (en) Modified adenoviruses
US9744224B2 (en) Methods for treating cancer by administration of nucleic acids encoding FAP and cancer antigens
CN103221544A (zh) 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体
CN112368007A (zh) 抗原隐匿的溶瘤病毒
ES2692389T3 (es) Terapia antitumoral mejorada mediante virus oncolíticos dirigidos a células madre tumorales
JP2024177358A (ja) 腫瘍溶解性遺伝子改変麻疹ウイルスの新規用途
Santry Lisa A. Santry, Jacob P. van Vloten, Amanda WK AuYeung, Robert C. Mould, Jacob GE Yates, Thomas M. McAusland, James J. Petrik 2, Pierre P. Major 3, Byram W. Bridle and Sarah K. Wootton
KR20230095830A (ko) 면역 회피성 항종양 아데노바이러스
HK40030481A (en) Modified adenoviruses
HK40030481B (en) Modified adenoviruses
Sostoa Pomés Oncolytic adenoviruses expressing transgenes targeting the tumor stroma to enhance the antitumor efficacy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination